BIIB VS JNJ Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

BIIB
74/100

BIIB returned -15.64% in the last 12 months. Based on SPY's performance of -20.65%, its performance is above average giving it a score of 74 of 100.

JNJ
73/100

JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.

Analyst Price Targets

BIIB
73/100

32 analysts offer 12-month price targets for BIIB. Together, they have an average target of 294.73, the most optimistic target put BIIB at 405 within 12-months and the most pessimistic has BIIB at 209.

JNJ
63/100

23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Sentiment

BIIB
70/100

BIIB had a bullish sentiment score of 70.25% across Twitter and StockTwits over the last 12 months. It had an average of 66.53 posts, 492.48 comments, and 835.41 likes per day.

JNJ
72/100

JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.

Technicals

BIIB
14/100

BIIB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

JNJ
14/100

JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

BIIB
61/100

BIIB has missed earnings 2 times in the last 20 quarters.

JNJ
100/100

JNJ has missed earnings 0 times in the last 20 quarters.

Profit

BIIB
64/100

Out of the last 20 quarters, BIIB has had 19 profitable quarters and has increased their profits year over year on 6 of them.

JNJ
74/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

BIIB
40/100

BIIB has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

JNJ
43/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Dividend

BIIB

"Dividend" not found for BIIB

JNJ
100/100

JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Biogen Inc. Common Stock Summary

Nasdaq / BIIB
Healthcare
Drug Manufacturers - General
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Johnson & Johnson Summary

New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.